PHENOMICS HEALTH

Serial Number 97023072
602

Registration Progress

Application Filed
Sep 12, 2021
Under Examination
Approved for Publication
Published for Opposition
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: PHENOMICS HEALTH
Previous Owner: Phenomics Health Inc.
Classes: 042, 044

Trademark Image

PHENOMICS HEALTH

Basic Information

Serial Number
97023072
Filing Date
September 12, 2021
Abandonment Date
February 18, 2025
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Mar 3, 2025
Classes
042 044

Rights Holder

Phenomics Health Inc.

03
Address
46701 Commerce Center Drive
Plymouth, MI 48170

Ownership History

Phenomics Health Inc.

Original Applicant
03
Plymouth, MI

Legal Representation

Attorney
Roger H. Bora

USPTO Deadlines

All Deadlines Cleared

All 1 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

21 events
Date Code Type Description Documents
Mar 3, 2025 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
Mar 3, 2025 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Nov 11, 2024 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Nov 11, 2024 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Aug 14, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 14, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 14, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 29, 2023 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Aug 18, 2023 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Feb 1, 2023 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Feb 1, 2023 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Feb 1, 2023 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jan 3, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 3, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 3, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 5, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 5, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jul 5, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 15, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 19, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 15, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Scientific and technological services featuring testing, analysis and evaluation of human blood and other biological samples for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services featuring testing, analysis and evaluation of blood samples for the purpose of improving quality in the field of healthcare services, specifically for improving the monitoring and diagnostics of quantitative patient drug exposure, monitoring and diagnostics of patient drug compliance, data-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activities, drug dosage recommendations, initial drug prescribing, and drug switching, all for research purposes and not for medical purposes; Software as a service (SaaS) services featuring software for use in medical research data collection and management and database management, allowing physicians to share and receive clinical data, monitor patient data, monitor patient clinical data, monitor medications in a patient's circulation to support treatment decisions, develop clinical treatment decision support, develop other medical diagnostic products and prescription drugs for the purpose of improving patient outcomes in the field of healthcare, analyze and record testing, analysis and evaluation of human blood and other biological samples for the purposes of improving the identification and quantitative measurement of patient drug exposure, improving the monitoring and diagnosis of patient drug compliance, improving drug selection and dosage recommendations, improving the initial drug prescribing practices, and identifying drug-drug interactions; Platform as a Service (PaaS) featuring computer software that allows users to monitor patient data, patient clinical data, and medications in a patient's circulation to support treatment decisions; Providing an interactive website featuring technology that allows users to monitor patient data, patient clinical data, and medications in a patient's circulation to support treatment decisions; scientific and technological services, namely, providing medical and scientific research featuring testing, analysis and evaluation of blood samples for the purpose of improving the identification and quantitative measurement of patient drug exposure, improving the monitoring and diagnosis of patient drug compliance, improving drug selection and dosage recommendations, improving initial drug prescribing practices, identifying drug-drug interactions, developing clinical treatment decision support, and developing other medical diagnostic products and prescription drugs; scientific and technological services in the nature of testing, analysis and evaluation of blood and other biological samples for research purposes in the field of clinical trials; scientific and technological services, namely, research, analysis, and clinical testing in the fields of precision medicine for the purpose of combining pharmacogenomic drug treatment recommendations, identification and quantitative measurement of patient drug exposure with digital patient monitoring and digital therapy
Class 044
Medical testing, analysis, and evaluation services relating to the diagnosis and treatment of disease and other medical conditions, namely, testing, analysis and evaluation of blood and other biological samples for clinical treatment decision support purposes; Medical testing, analysis, and evaluation services in the nature of testing, analysis and evaluation of blood samples for diagnostic and treatment purposes; Medical testing, analysis, and evaluation services relating to the diagnosis and treatment of disease and other medical conditions in the nature of testing, analysis and evaluation of blood samples for the purpose of combining increased predictability of patient-specific drug efficacy, appropriate dose, drug-drug interactions, and likely adverse drug reactions with precise measurement of patient response to improve patient treatment outcomes, avoid adverse drug reactions, and reduce patient treatment costs

Additional Information

Pseudo Mark
PHONEMICS HEALTH

Classification

International Classes
042 044